Search
Diphenoxylate
go.drugbank.com/drugs/DB01081ApprovedIllicitInvestigationalThis medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations.
Dirucotide
go.drugbank.com/drugs/DB04921InvestigationalDeveloped at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp.
PA-1050040
go.drugbank.com/drugs/DB06039ExperimentalIt inhibits virus replication by the same mechanism of action as BVM.
Givosiran
go.drugbank.com/drugs/DB15066Approved[L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder
Corticosterone
go.drugbank.com/drugs/DB04652InvestigationalAn adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.
Profenamine
go.drugbank.com/drugs/DB00392ApprovedProfenamine (also known as ethopropazine) is a medication derived from phenothiazine. It is primarily used as an antidyskinetic to treat Parkinsonism. It is sold under the trade name Parsitan in Canada. In the US, the marketing of profen...
Oteseconazole
go.drugbank.com/drugs/DB13055ApprovedInvestigational[L41635] This drug was approved by the FDA on April 26, 2022.[L41645] … [L41635,A247020] By binding and inhibiting CYP51, oteseconazole is active against most microorganisms associated with recurrent vulvovaginal candidiasis (RVVC).
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigational[L46287] It was fully approved by the EMA in May 2023.[L46596] … [A248745] Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults.
Aldosterone
go.drugbank.com/drugs/DB04630InvestigationalA hormone secreted by the adrenal cortex that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium.
Axitinib
go.drugbank.com/drugs/DB06626ApprovedInvestigationalAxitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).